Menu +

Corcept Therapeutics to Announce Second Quarter Financial Results Provide Corporate Update and Host Conference Call

Download this Press Release     Download this Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT) todayannounced it will report second quarter financial results and provide a corporate update on August 9, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

About Corcept Therapeutics Incorporated
To participate, dial 1-888-394-8218 from the United States or 1-323-794-2588 internationally approximately 10 minutes before the start of the call. The passcode is 6703650.

A replay will be available through August 23, 2018 at 1- 888-203-1112 from the United States and1- 719-457-0820 internationally. The passcode will be 6703650.

CORT 108297 is the lead compound from our three series of proprietary selective GR-II antagonists and is a fused-ring azadecalin. This series of compounds has demonstrated a greater than 1000-fold difference in binding affinity for the GR-II receptor compared to the PR receptor.

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.

Investor Relations
Corcept Therapeutics

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue